Posted by Michael Wonder on 24 Feb 2023
Enhertu approved in China for patients with HER2 positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
24 February 2023 - First approval for AstraZeneca and Daiichi Sankyo’s Enhertu in China.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens.
Approval based on DESTINY-Breast03 results where Enhertu demonstrated a 72% reduction in the risk of disease progression or death versus trastuzumab emtansine.
